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AbstrAct
Werner syndrome protein (WRN) is a RecQ helicase that participates in DNA 
repair, genome stability and cellular senescence. The five human RecQ helicases, 
RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell 
survival after treatment with the anticancer drug camptothecin (CPT). CPT derivatives 
are widely used in cancer chemotherapy to inhibit topoisomerase I and generate DNA 
double-strand breaks during replication. Here we studied the effects of CPT on the 
stability and expression dynamics of human RecQ helicases. In the cells treated with 
CPT, we observed distinct effects on WRN compared to other human RecQ helicases. 
CPT altered the cellular localization of WRN and induced its degradation by a ubiquitin-
mediated proteasome pathway. WRN knockdown cells as well as CPT treated cells 
became senescent and stained positive for senescence-associated β-galactosidase 
at a higher frequency compared to control cells. However, the senescent phenotype 
was attenuated by ectopic expression of WRN suggesting functional implication of 
WRN degradation in CPT treated cells. Approximately 5-23% of breast cancer tumors 
are known to respond to CPT-based chemotherapy. Interestingly, we found that the 
extent of CPT-induced WRN degradation correlates with increasing sensitivity of 
breast cancer cells to CPT. The abundance of WRN decreased in CPT-treated sensitive 
cells; however, WRN remained relatively stable in CPT-resistant breast cancer cells. In 
a large clinical cohort of breast cancer patients, we find that WRN and topoisomerase 
I expression correlate with an aggressive tumor phenotype and poor prognosis. Our 
novel observations suggest that WRN abundance along with CPT-induced degradation 
could be a promising strategy for personalizing CPT-based cancer chemotherapeutic 
regimens.
INtrODUctION
The RecQ family of helicases contains highly 
conserved and ubiquitously expressed proteins that unwind 
DNA in the context of replication, repair, transcription, 
chromatin remodeling and telomere maintenance [1, 2]. 
Human and most mammalian cells encode five RecQ-
like (RECQL) helicases: RECQL1, Bloom (BLM), 
Werner (WRN), RECQL4 and RECQL5. These helicases 
display unique as well as overlapping functions in DNA 
metabolism. They bind specific DNA structures and 
catalyze unwinding and annealing of DNA strands to 
resolve DNA replication forks, D-loops, G-quadruplex 
structures and Holliday junctions [1, 2]. Mutations in 
BLM, WRN and RECQL4 are associated with autosomal 
recessive diseases. Loss of function of BLM and WRN 
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is associated with Bloom syndrome (BS) and Werner 
syndrome (WS) respectively, while RECQL4 is associated 
with Rothmund-Thomson (RTS), RAPADILINO and 
Baller-Gerold (BGS) syndromes[1-3].
In general, cells with defects in DNA repair have 
increased risk of transformation to a pre-cancer or 
cancer phenotype. WS and BS patients exhibit increased 
incidence of cancer. The most common neoplasias in 
WS patients are thyroid cancer, malignant melanoma, 
meningioma, soft tissue sarcoma, osteosarcoma, breast 
cancer and leukemias [3, 4]. Increased WRN expression 
is observed in several cancer cell lines and depletion of 
WRN induces cell death in these cells [5]. Irinotecan 
treatment enhanced the survival of colorectal cancer 
patients who expressed lower WRN [6].
The plant alkaloid camptothecin (CPT) and its 
derivatives, irinotecan and topotecan, represent an 
important class of drugs used in chemotherapy. These 
drugs specifically target DNA topoisomerase I (Top1), 
an enzyme that transiently creates DNA single-strand 
breaks to reduce supercoiling during replication and 
transcription [7, 8]. CPT generates cytotoxic covalent 
reaction intermediates, CPT-DNA-Top1, by inhibiting the 
re-ligation step of the Top1 catalytic cycle. The cytotoxic 
effect of the CPT-DNA-Top1 intermediate is S-phase-
specific, and is thought to reflect collision events between 
the replication machinery and the cytotoxic lesion [7, 8]. 
When cells accumulate many CPT-DNA-Top1 lesions, the 
DNA damage response (DDR) and associated pathways 
are activated [8]. Subsequent to DDR activation, DNA 
repair factors, including RecQ helicases are recruited 
to the DNA lesions and/or to stalled DNA replication 
forks. All human RecQ helicases are important for cell 
survival after CPT treatment [9-13]. WS and BS patient 
cells are hypersensitive to inhibitors of Top1 and DNA 
interstrand crosslinking agents, and a synergistic increase 
in chromosomal aberrations is observed in BLM-WRN 
double knockout cells exposed to these agents [11]. 
RECQL4-deficient RTS patient cells and RECQL1 and 
RECQL5 knockdown cells are also sensitive to CPT [9, 
12, 13]. However, studies identifying the mechanisms by 
which CPT or its analogs exert their effects on human 
RecQ helicases are limited. In this study, we tested the 
effects of CPT on the five RecQ helicases in cellular 
studies and bioinformatically analyzed the association 
between CPT sensitivity and WRN gene expression. 
Further we analyzed the expression profiles of WRN 
and Top1 in a large cohort of human breast cancers to 
identify any correlations between gene expression and 
breast cancer specific survival. This study spans from 
biochemical and cellular work through bioinformatics to 
a clinical study.
CPT treatment specifically altered the stability and 
subcellular localization of WRN, while similar effects 
on other RecQ helicases were not observed. In CPT-
treated cells, a large fraction of WRN re-localized to the 
cytoplasm and was selectively degraded by the ubiquitin 
proteasome pathway. CPT-induced WRN degradation was 
independent of p53 status, and the extent of degradation 
was associated with the sensitivity of the tumor cells to 
the anticancer drug. WRN degradation was more extensive 
in CPT-sensitive breast cancer cells than in CPT-resistant 
cells. However, CPT-dependent degradation of Top1 
was extensive in all cell lines tested. In the METABRIC 
(Molecular Taxonomy of Breast Cancer International 
Consortium) cohort comprising 1977 breast cancers, ~20% 
of tumors were found to express high Top1 mRNA and 
~83% were found to express high WRN mRNA. Altered 
Top1 and WRN expression was not only associated with 
aggressive breast cancers but also correlated with adverse 
prognostic outcome in patients. Interestingly, in patients 
with estrogen receptor (ER)-positive breast cancers, high 
WRN and high Top1 levels were associated with a bad 
prognosis. Together these results suggest that WRN, 
but not the other RecQs, is a target of CPT in mediating 
chemotherapeutic effects in the tumor cells.
rEsULts
stability, expression and subcellular distribution 
of WrN in cPt-treated cells
CPT and its derivatives specifically target Top1, 
and the five human RecQ helicases play essential roles 
in cell survival after CPT treatment [9-13], thus we tested 
the effects of CPT on the expression dynamics of all 
five human RecQ helicases to identify unique or shared 
responses to CPT treatment.
U2OS cells were treated with 10 μM CPT for 1, 
2, 6, 8 or 10 hours, and lysed with IP lysis buffer [14]. 
Proteins in the supernatant fraction, obtained after 
centrifugation, were analyzed by immunoblotting for 
WRN, BLM, RECQL1, RECQL4, RECQL5, Ku80, CtIP 
and XLF (Figure 1a). Exposure to CPT caused a decrease 
in the abundance of WRN protein, but not of the other 
proteins tested (Figure 1a and 1b). Quantification of the 
immunoblots indicated that WRN protein decreased 
significantly in a time-dependent manner from ~1 to 10 h 
after treatment with CPT (Figure 1a graph). This reduction 
was not observed for BLM, RECQL1, RECQL4 and 
RECQL5 or for the DNA repair proteins Ku80, CtIP, and 
XLF (Figure 1a and 1b). The half-life of WRN protein 
is reported to be approximately 6 h [15], consistent with 
its apparent half-life in this study (Figure 1a graph). 
Interestingly, cells treated with 1 or 10 Gy ionizing 
radiation (IR) did not show a decrease in WRN abundance 
at time points up to 10 h after irradiation (Figure 1c). 
These results indicate that the effect of CPT on WRN 
protein levels could be specific.
The mRNA transcripts encoding all five RecQ 
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helicases were also quantified in CPT-treated and 
untreated cells (Figure 1d). For all RecQ helicases, 
transcript abundance was unaffected up to 24 h with CPT 
treatment. This indicates that CPT induces (Figure 1a) 
specific post-translational degradation of WRN protein, 
or that it destabilizes WRN protein by another mechanism.
WRN protein distribution was analyzed in U2OS 
cells stably expressing YFP-WRN and treated with 
CPT using confocal microscopy (Figure 2a). Live-cell 
microscopy results indicated that YFP-WRN localized 
primarily to the nucleolus, re-localized to the nucleoplasm 
~60 min after exposure to CPT, after which YFP-WRN 
Figure 1: Expression of recQ helicases in cPt and Ir treated cells. a. Half-life of DNA repair proteins in CPT treated cells. 
Lysates from U2OS cells were treated with 10 µM CPT for the indicated times and immunoblotted for DNA repair proteins viz., Ku70, CtIP, 
XLF and the RecQ helicases WRN, BLM, RECQL1, RECQL4 and RECQL5. Below; graph showing the relative levels of WRN protein 
normalized to tubulin from three independent experiments. b. Bar graph showing the protein levels of RecQ helicases in CPT treated cells. 
c. Immunoblots showing the expression of DNA repair proteins as in panel A from IR treated U2OS cells. d. Quantitative RT-PCR analysis 
showing mRNA levels of RecQ genes in CPT treated U2OS cells. Expression of GAPDH mRNA was used for normalization. Error bars 
represent standard deviation from two independent experiments. 
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fluorescence declined to a low level in the nucleolus 
(Figure 2a). YFP-WRN foci were also observed in the 
nucleoplasm of CPT-treated cells, suggesting recruitment 
of WRN to CPT-induced DNA damage. To examine 
the subcellular distribution of WRN, proteins from the 
cytoplasm, cytoplasmic organelles, nuclear-soluble 
and chromatin fractions were isolated and analyzed by 
Western blotting (Figure 2b). The results suggest that 
WRN is enriched in cytoplasmic organelles (Figure 2b, 
compare lane 5 with 6-8) after CPT treatment. Analysis 
of subcellular protein fractions from IR treated cells did 
not show significant changes in the distribution pattern of 
WRN compared to untreated cells (Supplementary Figure 
S1a). Further, results from immunostained cells indicated 
that endogenous WRN resides in the nucleolus of cells 
(Figure 2c top panel and [16]) and that, upon treatment 
with CPT, re-localizes to the nucleoplasm and cytoplasm 
(Figure 2c bottom panels). To test the role of translation 
in CPT-dependent enrichment of WRN in the cytoplasmic 
organelle fraction observed in Figure 2b, cells were treated 
with cycloheximide (CHX) along with CPT. Inhibition 
of translation did not affect CPT-induced re-localization 
of WRN (Supplementary Figure S1b), suggesting that 
the WRN enrichment is not dependent on new protein 
synthesis. Collectively these results demonstrate that 
WRN undergoes re-localization in cancer cells treated 
with CPT.
Figure 2: cPt-induced re-localization of WrN. a. Dynamic distribution of YFP-WRN in CPT-treated cells. Live cell time-lapse 
micrographs from CPT (10 µM) treated U2OS cells stably expressing YFP-WRN. Arrows point the nucleus of YFP-WRN expressing cells. 
b. WRN distribution in the subcellular compartments. Immunoblots indicating the relative levels of WRN in the cytoplasmic, cytoplasmic 
organelle, nuclear soluble and chromatin fractions of U2OS cells treated with and without CPT. Time indicate the length of the exposure to 
CPT. c. Enrichment of endogenous WRN in the cytoplasm. Confocal microphotographs showing WRN and 53BP1 localization in U2OS 
cells treated with CPT. Representative images from two independent experiments. Microscope images were taken with 40X objective.
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cPt-induced ubiquitination and degradation of 
WrN
To identify the CPT concentrations that induce 
WRN degradation, U2OS cells were treated with 0.01, 
0.05, 0.1, 0.5, 1, 5, 10 and 20 µM CPT for 16h and 
extracts were prepared by lysing the cells with RIPA buffer 
followed by brief sonication. Our results showed that the 
WRN protein is downregulated in cells exposed to 0.5 to 
20 µM CPT, conditions that induce degradation of Top1 
(Figure 3a and Supplementary Figure S2a). We previously 
reported that WRN interacts with Top1 [17] and other 
studies have shown that CPT-induced degradation of 
Top1 occurs in an ubiquitin- and proteasome-dependent 
manner [18, 19]. Therefore, it seemed possible that WRN 
downregulation might be ubiquitin- and proteasome-
dependent. Consistent with this possibility, the proteasome 
inhibitor MG132 suppressed CPT-induced degradation of 
WRN and Top1 in cells treated with 1 µM CPT (Figure 
3b and Supplementary Figure S2b). Further, when 293T 
cells co-expressing 3xFlag-WRN and HA-ubiquitin 
were treated with CPT and MG132 (Figure 3c), and 
cell lysates were analyzed after immunoprecipitation, 
ubiquitin and WRN co-immunoprecipitated with HA or 
FLAG antibodies. MG132 stabilized HA-ubiquitinated 
Flag-WRN, implicating proteasome-mediated degradation 
of WRN in CPT-treated cells (Figure 3c). We found no 
Figure 3: Ubiquitin proteasome-mediated degradation of WrN in cPt treated cells. a. CPT-induced WRN down regulation 
is associated with Top1 degradation. Immunoblots showing WRN and Top1 protein levels in U2OS cells treated with indicated concentration 
of CPT for 16 h. b. Proteasome inhibitor MG132 inhibits the effect of CPT on WRN and Top1. U2OS cells were treated with 10 µM 
MG132 to inhibit proteasome pathway and with 10 µM E64 to inhibit lysosome pathway. c. Ubiquitination of WRN in CPT treated 
cells. Immunoblots showing ubiquitinated (HA-ubiqutin) 3xFlag-WRN in immuno precipitated fractions of CPT (1µM) treated 293T cells 
expressing 3xFlag-WRN and HA-ubiqutin. 
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evidence that WRN was enriched in lysosomes, using 
cells in which the lysosome was fluorescence-labeled with 
lysosome-specific GFP (Supplementary Figure S3). These 
results suggest that CPT-stimulated degradation of WRN 
is lysosome-independent, but ubiquitin- and proteasome-
dependent.
WrN attenuates cPt-induced cellular senescence
To explore the functional consequences of WRN 
downregulation in CPT treated cells, we analyzed cell 
survival and cellular senescence after CPT treatment. 
Compared to control cells, WRN depleted cells displayed 
dose-dependent reduction in cell viability in the 
presence of CPT (Supplementary Figure S4a). However, 
Figure 4: WrN attenuates cPt-induced cellular senescence. a. Knockdown of WRN induces cellular senescence in human 
fibroblasts. Left, micrographs showing SA-β-gal stained GM637 cells; right, bar graph showing SA-β-gal positive cells (n = three 
independent experiments). Immunoblots showing knockdown levels of WRN. shCtrl, control shRNA; shWRN, WRN shRNA b. CPT-
induced cellular senescence in human fibroblasts. Bar graph showing SA-β-gal positive GM637 cells treated with CPT for 18 h. Error bars 
represent standard deviation from two independent experiments. Immunoblots indicate WRN degradation after CPT treatment. c. Ectopic 
expression of WRN attenuates CPT-induced cellular senescence. GM637 cells transfected with vector, Flag-WRN and Flag-RECQL4 were 
treated with indicated CPT concentrations and stained for SA-β-gal (n = three independent experiments).
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knockdown of RECQL4 did not increase the sensitivity 
of cells to CPT. These results suggest a distinct protective 
role of WRN against the cytotoxic effects of CPT. 
It is well established that DNA damage induces 
cellular senescence [20], and we and others have shown 
that WRN plays a role in preventing this process [21, 22]. 
Because the results presented above showed that WRN 
is downregulated in CPT-treated cells we hypothesized 
that decreased abundance of WRN could exacerbate 
CPT-induced senescence. To test this possibility, we 
Figure 5: WrN degradation is associated with sensitivity of tumor cells to cPt. a. WRN expression and CPT sensitivity of 
breast cancer cells lines. Graph showing Z scores of WRN transcript expression and CPT sensitivity as documented in NCI-60 Cell Miner 
database. Z score for WRN transcript intensity indicates relative mRNA expression compared to average expression of NCI-60 panel of cell 
lines. Negative Z score for CPT sensitivity indicates the resistance of the cell line to CPT. b. WRN protein expression in tumor cell lines. 
c. CPT-dependent WRN degradation in CPT-sensitive and CPT-resistant breast cancer cell lines. Immunoblots represents protein levels in 
cells treated with CPT for 16 h. Graphs showing relative degradation of WRN d. and Top1 e. in breast cancer cell lines treated with 10 µM 
CPT. f. CPT-dependent cell viability and proliferation in sensitive and resistant breast cancer cells. Graph showing relative cell proliferation 
after 24 h of CPT (0.01 to 10 µM) treatment. Error bars represent SEM from three independent experiments.
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measured senescence-associated β-galactosidase (SA-β-
gal) activity, a marker of senescence [21], in fibroblasts 
and U2OS cells treated with CPT. Knockdown of WRN in 
human fibroblasts, GM0637, induced cellular senescence 
in ~60% of the cell population (Figure 4a). Treatment of 
cells with 5 and 20 µM CPT, levels that downregulated 
WRN, also induced senescence in ~35 and ~45% of cells, 
respectively (Figure 4b). To evaluate any protective role(s) 
that WRN may provide against CPT-induced cellular 
senescence, GM0637 cells were transfected with 3xFlag-
WRN (Supplementary Figure S4b) for 24 hours before 
treatment with CPT. Consistent with the results obtained 
in the untransfected cells (Figure 4b), vector-transfected 
cells exposed to 5 and 20 µM CPT accumulated ~35 and 
~40% senescent cells. However, vector-transfected cells 
treated with DMSO only accumulated ~8% senescent cells 
(Figure 4c) and the ability of CPT to induce the senescent 
phenotype was attenuated in cultures expressing 3xFlag-
WRN (Figure 4c). The 3xFlag-WRN expressing cultures 
contained ~14% and ~24% senescent population in the 
presence of DMSO and CPT, respectively (Figure 4c). 
Similar results were observed in U2OS cells expressing 
C-terminal GFP-tagged WRN (Supplementary Figure 
S4c). However, ectopic expression of 3xFlag-RECQL4 
(Supplementary Figure S4b) did not significantly inhibit 
CPT-induced cellular senescence (Figure 4c). These 
results demonstrate that WRN provides partial protection 
against CPT-induced cellular senescence.
WrN degradation and cPt sensitivity in breast 
cancer cells
A specific mutation (Phe1074Leu) in WRN is found 
to increase the risk of breast cancer incidence [23, 24], 
and dysregulation of WRN expression is observed in 
breast cancer cells lines [5, 6]. Lately there has been an 
interest in using Top1 inhibitors in the treatment of breast 
cancer [25, 26], which traditionally has been treated with 
other approaches. Since Top1 protein expression is tightly 
correlated with mRNA expression in various cancer cell 
lines [27] and the above results show that WRN and 
Top1 are targets for degradation in CPT treated cells, we 
conducted an in silico search to find correlations between 
the steady-state expression of Top1 and WRN and the 
sensitivity to Top1 inhibitors using Cancer Cell Line 
Encyclopedia (CCLE) and Cancer Genome Atlas (TGCA) 
databases. The results suggest that, irrespective of cancer 
types, toptecan sensitivity is generally associated with 
Top1 (p-value = 7.7e-03) and WRN (p-value = 2.27e-06) 
mRNA expression (Supplementary Figure S5a, S5b and 
5c). Additionally, mining of breast cancer specific RNAseq 
data from TCGA, indicated a strong correlation between 
Top1 and WRN expression (Supplementary Figure S5a; r 
= 0.325, p = 5.83e-26) suggesting the importance of these 
two genes in breast cancer.
To investigate WRN and Top1 expression and the 
phenomenon of CPT-induced WRN degradation in breast 
cancer cells, we used three CPT-sensitive (MCF-7, T47D 
and ZR-75-1) and three CPT-resistant (BT549, MDA-
MB-231 and BT-474) cell lines. The Cell Miner database 
(http://discover.nci.nih.gov/cellminer/) information on the 
breast cancer cell lines showed that WRN expression was 
low in two of the CPT-sensitive cell lines (MCF-7 and 
T47D), high in one CPT-resistant cell line (BT-549) and 
low in another CPT-resistant (MDA-MB-231) cell line 
(Figure 5a). Western blot analysis of WRN in the six breast 
cancer cell lines showed that these cells expressed WRN at 
relatively similar levels (within 20% of each other: Figure 
5b). However, upon treatment with CPT, a significant 
difference in WRN degradation was observed between 
the CPT-sensitive and -resistant cell lines (Figure 5c). The 
Figure 6: top1 and WrN mrNA expression in MEtAbrIc cohort. Kaplan Meier curves showing BCSS (Breast cancer 
specific survival) based on Top1 expression a. and WRN expression b.
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table 1: clinico-pathological characteristics of MEtAbrIc cohort based on WRN and Top1 expression
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CPT-sensitive cells showed significant WRN degradation 
after CPT treatment, whereas the CPT-resistant cells 
showed minimal WRN degradation (Figure 5c and 5d). 
In contrast, CPT-induced Top1 degradation was extensive 
in both (Figure 5c and 5e) demonstrating that Top1 has no 
predictive power and further that dose was sufficient to 
induce degradation in all cell lines. 
A seminal study reported a high degree of 
heterogeneity in Top1 degradation after CPT treatment 
[28]. Our results confirm this observation in MCF-7, 
T47D, HCT116, and WI38 cell lines treated with CPT 
for 8 h (Supplementary Figure S6a); however Top1 was 
extensively degraded in all tested cell lines, including ZR-
75-1, after 16 h of treatment (Figure 5c and Supplementary 
Figure S6a and S6b). Supporting the importance of WRN 
in cell proliferation after DNA damage, CPT-sensitive 
breast cancer cells, which displayed drug-induced WRN 
degradation, showed compromised cell proliferation after 
CPT treatment (Figure 5f). Cell survival and proliferation 
of CPT-resistant cells was largely unaffected by CPT 
(Figure 5f). Together these results demonstrate that CPT-
sensitivity correlated with WRN degradation and not Top1 
degradation.
Top1 and WRN mrNA expression in human 
breast cancers
Given the essential role of WRN and Top1 in 
DNA repair and replication we studied their role in 
breast cancer pathogenesis and prognosis. Inhibition of 
WRN promoter methylation increased the WRN mRNA 
levels which in turn increased the protein levels in 
several cancer cells [6], and a tight correlation between 
Top1 mRNA and protein expression was observed in 
the NCI-60 panel of cell lines [27] implying that high 
mRNA leads to high protein expression. Therefore we 
investigated the mRNA levels of WRN and Top1 in the 
METABRIC (Molecular Taxonomy of Breast Cancer 
International Consortium) cohort. Primary tumors were 
expression profiled [29] to investigate associations with 
clinic-pathological parameters and survival in patients. 
Nearly 16.5% (326/1977) of tumors had low WRN mRNA 
expression and ~85.5% (1651/1977) tumors had high 
WRN mRNA expression (Figure 6a). Low WRN mRNA 
expression was significantly associated with aggressive 
clinicopathological features including high histological 
grade, lymph node stage, high risk Nottingham prognostic 
index (NPI) > 3.4 and Her-2 over expression (ps≤0.01) 
(Table 1). Interestingly, ER negative and triple negative 
phenotypes were more common in tumors with high 
WRN mRNA expression (ps≤0.01). Low WRN mRNA 
expression was significantly associated with molecular 
phenotypes: PAM50.Her2, PAM50.LumB, Genufu 
subtype (ER+/Her2-/High proliferation) and Genufu 
subtype (Her2 positive) breast tumors (ps≤0.01). On the 
other hand, PAM50.LumA tumors, PAM50.basal and 
Genufu subtype (ER+/Her2-/low proliferation) express 
high levels of WRN mRNA (ps≤0.01). Similarly, the WRN 
mRNA level was significantly associated with the various 
integrative clusters (Table 1) described in the METABRIC 
study which was based on gene copy number changes and 
gene expression data [29]. Low WRN mRNA expression 
was significantly associated with clusters, which had poor 
clinical outcome in the METABRIC study [29]. Low 
WRN mRNA expression in tumors was associated with 
adverse Breast Cancer Specific Survival (BCSS) in the 
whole cohort (p = 0.002) (Figure 6a). The data provides 
evidence that low WRN mRNA expression is associated 
with aggressive phenotypes and poor survival in patients. 
In the METABRIC cohort, ~20% (390/1977) 
of tumors had high Top1 mRNA expression and 80% 
(1586/1977) tumors had low Top1 mRNA expression 
(Figure 6b). High Top1 mRNA expression was significantly 
associated with aggressive clinicopathological features 
including high histological grade, larger tumor size, high 
risk Nottingham prognostic index (NPI) > 3.4, Her2 over 
expression, and ER- and PR- tumors (ps < 0.05) (Table 1). 
High Top1 mRNA expression in tumors was associated 
with adverse BCSS in the whole cohort (p = 0.002) (Figure 
6b). Of note, patients in the METABRIC cohort did not 
receive Top1 inhibitor based therapy. Nevertheless, taken 
together, the data provides evidence that high Top1 mRNA 
expression is associated with aggressive breast cancers.
WrN and top1 co-expression in Er positive and 
Er negative breast cancers
Our in vitro results suggest that WRN degradation 
could be a useful marker in personalized chemotherapy. To 
identify potential patient populations that may benefit from 
CPT-based regimens, we proceeded to sub-group analysis 
of patients in the METABRIC cohort where ER positive 
tumors comprised of 1507/1977 (76.2%) of tumors and 
470/1977 (23.8%) were ER negative tumors. 
When Top1 and WRN were combined together, as 
expected, patients with high WRN/high Top1 expressing 
tumors had worst survival compared to tumors with low 
WRN/low Top1 expression in the whole cohort (p < 
0.0001) (Figure 7a and Supplementary Table 1) as well 
as in the ER positive cohort (p < 0.0001) (Figure 7b). In 
addition, in high risk ER positive tumors that received 
adjuvant endocrine therapy, high WRN/high Top1 
expressing tumors was associated with poor survival (p < 
0.001) (Supplementary Figure S7a). In ER positive tumors 
that received no endocrine therapy, high WRN/high Top1 
expressing tumors remains associated with poor survival 
compared to tumors with low WRN/low Top1 expressing 
(p = 0.006) (Supplementary Figure S7b). 
Interestingly, when WRN and Top1 examined were 
combined in ER negative tumors, low WRN/low Top1 
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Figure 7: Kaplan Meier curves showing bcss with WrN and top1 expression. a. WRN and Top1 expression in whole 
cohort. b. and c. combined expression of WRN and Top1 in ER positive and ER negative METABRIC cohorts.
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expressing tumors had the worst survival compared to 
patients with high WRN/high Top1 expressing tumors (p 
= 0.021) (Figure 7c). Collectively, the data suggest that 
WRN/Top1 expression may have predictive significance 
in the ER negative sub-group. In patients who had no 
adjuvant chemotherapy, compared to tumors with low 
WRN/low Top1 expression, tumors with high WRN/
high Top1 expression have a poorer prognosis (p = 0.043) 
(Supplementary Figure S7d). 
Taken together, in ER positive tumors WRN/
Top1 co-expression may have predictive significance in 
patients who received endocrine therapy and prognostic 
significance in patients who received no endocrine therapy. 
Importantly, the data also suggest that an alternative 
form of therapy such as those targeting Top1 could be a 
promising strategy in high Top1/high WRN expressing 
tumors. Overall these results identify that ~14% of ER 
positive and ~34% of ER negative breast cancer patients 
express high WRN and high Top1 in their tumors and may 
benefit from CPT-based personalized chemotherapy.
DIscUssION
Cellular studies show that RecQ helicases protect 
against the cytotoxic effects of CPT [9-13]. To characterize 
the mechanism, we analyzed the expression and stability 
of the human RecQ helicases in cells exposed to CPT. CPT 
affects the degradation of WRN protein without altering 
expression of WRN mRNA or the abundance of the other 
RecQ proteins. CPT treatment resulted in re-localization 
of WRN from the nucleolus to the nucleoplasm and 
cytoplasmic organelles, and resulted in downregulation of 
the protein in a time- and CPT concentration-dependent 
manner. CPT-induced WRN downregulation was mediated 
by the ubiquitin proteasome pathway, and ectopic 
expression of WRN attenuated the CPT-induced senescent 
phenotype. Drug-induced WRN degradation in breast 
cancer cell lines was associated with the sensitivity of cells 
to CPT. Breast cancer patients with ER-positive tumors 
expressing high WRN and Top1 had poor survival. Overall 
findings presented in this study, based on cellular studies, 
in silico studies and clinical studies, suggest that WRN 
helicase along with Top1 can be targeted with CPT at the 
protein level and could be a used as a potential marker for 
predicting the efficiency of CPT-based chemotherapy for 
breast cancer.
WRN, the largest human RecQ protein, contains 
a nuclease domain, which is not found in other RecQ 
proteins, and catalyzes four DNA-dependent reactions: 
3’-5’-exonuclease, ATPase, DNA strand annealing and 
3’-5’-helicase activities. Through its enzymatic functions, 
WRN acts on various DNA structures to facilitate DNA 
repair. Mutations in WRN leads to defects in DNA 
repair, premature aging and to cancer susceptibility [23, 
30, 31]. Small molecules targeting DNA repair proteins 
have profound effects in inhibiting tumor survival. A 
recent study identified NSC 19630 [1-(propoxymethyl)-
maleimide] as a specific inhibitor of WRN, which 
synergistically inhibited cell proliferation and induced 
DNA damage with topotecan [32].
CPT and its analogs are used against a broad 
spectrum of tumors [33]. It covalently binds to the 
interface between Top1 and DNA, thereby blocking the 
cleavage/re-ligation activities of the topoisomerase [7]. As 
a result high loads of protein-linked DNA breaks block 
replication and transcription events and initiate senescence 
and cell death [8, 34]. The novel observation reported 
here is that WRN is specifically degraded in CPT-treated 
cells exacerbating the adverse consequences of CPT-
induced DNA damage and loss of functional Top1. CPT 
treatment leads to a reduction of Top1 protein, trapped 
as the CPT-DNA-Top1 complex, by small ubiquitin-
like modifier (SUMO) protein conjugation and by the 
ubiquitin proteasome pathway [18, 35, 36]. As shown 
here, CPT also causes the specific degradation of WRN, 
but not of the other RecQ helicases, likely because WRN 
physically and functionally interacts with Top1 [17]. Thus, 
the physical association between WRN and Top1 could 
lead to a shared ‘fate’ of degradation in CPT-treated cells. 
However, as shown in Figure 5c, Top1 degradation can be 
uncoupled from WRN degradation in certain cell types. 
Protein degradation is orchestrated mainly by the 
proteasome and lysosome proteolytic systems. Lack 
of KFERQ motifs in WRN suggests that it may not be 
targeted for degradation by lysosomes. Our results showed 
that CPT treatment induced re-localization of WRN from 
the nucleolus to the cytoplasm where ubiquitin-dependent 
protein turnover occurs. Ubiquitinylation of proteins 
occur by the addition of ubiquitin molecules to lysine 
residues on target proteins. In the G1 phase of the cell 
cycle, BLM is ubiquitinated and degraded to promote non-
homologous end joining [37]. Such degradation pathways 
might be operating on the other RecQ helicases depending 
on the cell cycle, as well as the functional contexts. 
Acetyltransferases CBP and p300 increased the stability 
of WRN in the presence of mitomycin C, and WRN 
stability and degradation was respectively associated 
with acetylation and ubiquitination of six lysine residues 
of the protein [15]. We observed ubiquitination of WRN 
after CPT treatment, suggesting decreased WRN stability 
due to protein degradation by the ubiquitin-proteasome 
pathway. However, the ubiquitin ligases that mediate CPT-
dependent ubiquitination of WRN are yet to be identified. 
Interestingly, CPT-induced WRN degradation was 
confined to CPT-sensitive cancer cells suggesting a role 
for WRN in rendering resistance against CPT. In addition 
to enhancing the enzymatic activity of Top1 [17], WRN’s 
nuclease and helicase activities might play critical roles 
in removing CPT-Top1-DNA cytotoxic lesions to reduce 
cytotoxic effects of the drug. Therefore it is possible that 
the WRN contributes to resistance to CPT by enhancing 
DNA repair capabilities at various levels. 
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Senescence is enhanced when RecQ helicases are 
deficient [21], or if there is persistent DNA damage [38] 
and after treatment with anticancer drugs like CPT [39]. 
In our recent report we demonstrated that knockdown of 
RecQ helicases (with the exception of RECQL1) resulted 
in the accumulation of DNA-SCARS (DNA segments with 
chromatin alternations reinforcing senescence), increased 
p21 and p16 along with increased SA-β-gal activity [21]. 
WRN knockdown and CPT treatment both induce DNA 
damage and cause increased p21 expression and SA-β-gal 
activity [39]. Here, we demonstrate that WRN degradation 
and increased senescence after CPT treatment can be 
suppressed by ectopically expressing WRN. Rescue of 
WRN in CPT-treated cells might increase the efficiency of 
DDR to remove cytotoxic DNA lesions.
Top1 gene amplification has been reported in about 
30% of breast cancers [40] and a tight correlation between 
mRNA and protein expression was observed in the NCI-
60 panel of cell lines [27]. Irinotecan, a semisynthetic 
derivative of CPT is routinely used in colorectal cancer 
therapy [41]. Although phase II trials have demonstrated 
a response rate of about 5% to 23%, irinitotecan is not 
routinely used as monotherapy in breast cancer [26]. 
However, etirinotecan, a long acting derivative of 
irinotecan has shown a response rate of 29% and is 
currently being evaluated in a large phase III clinical trial in 
metastatic breast cancer [25]. Given the potential promise 
of Top1 inhibitors in breast cancer, the development of 
predictive biomarkers to personalize therapy is highly 
desirable. In the current study, we suggest that CPT-
induced WRN degradation in breast cancer cells could be 
a biomarker for CPT sensitivity. Taken together, the pre-
clinical data show that WRN and/or Top1 expression could 
have prognostic and/or predictive significance in breast 
cancers. To explore this hypothesis, we conducted the first 
large study of WRN and Top1 expression in human breast 
cancers. We observed that Top1 mRNA overexpression 
was associated with aggressive highly proliferative breast 
cancers. In contrast, for WRN, low mRNA expression 
was associated with adverse clinicopathological features 
and was linked to poor breast cancer specific survival. 
Taken together, these novel observations suggest that 
low WRN expression in human tumors may promote 
a ‘mutator phenotype’ leading to aggressive breast 
cancers. Although the mechanism of regulation of WRN 
mRNA expression is not understood, Agrelo et al. have 
previously shown that epigenetic inactivation of WRN is 
frequent in solid tumors with the highest prevalence in 
colorectal tumors [37.9% (69/182 tumors)] [6]. In a small 
cohort of breast tumors (n = 58), 17.2% (10/58) showed 
WRN inactivation although the authors did not describe 
any clinicopathological associations in that study [6]. In 
our study, we have found that WRN mRNA expression 
level was low in 326/1977 of breast tumors (16.5%) 
which concur strikingly with the study by Agrelo et al. In 
colorectal cancers, WRN hypermethylation and depletion 
is associated with good response to irinotecan therapy 
[6]. We speculate that low WRN expression could result 
in a genomic instability phenotype with an aggressive 
behavior. To support this hypothesis, we observed that 
low WRN was associated with lymph node positivity, 
grade 3 and HER-2 overexpression. As the clinical study 
presented here provides prognostic information, future 
studies, particularly in patients who receive neoadjuvant 
chemotherapy (including Top1 inhibitor) could provide 
predictive information. 
When WRN and Top1 were combined, surprisingly 
we found that tumors with high Top1/high WRN expression 
have poor survival, particularly in the ER positive sub-
group. Top1 has essential roles during replication and 
proliferation. Highly proliferative ER positive breast 
tumors (PAM50. Lum B phenotype) manifest endocrine 
resistance. As high Top1 expression is significantly 
associated with PAM50. Lum B breast tumors (Table 1), 
we speculate that endocrine resistance may be contributing 
to the poor survival seen in patients. The data for WRN 
is intriguing. Whether WRN-mediated DNA repair in ER 
positive tumors would influence therapy outcome remains 
to be established. Interestingly, high expression of the 
multifunctional WRN helicase is observed in several 
cancer cell lines (Supplementary Figure S5 and [5]). As 
WRN participates in various DNA repair pathways, it is 
possible that it enhances the DNA repair capabilities of 
established tumor cells to withstand DNA damage induced 
by endogenous and exogenous agents. 
In conclusion, we provide the first pre-clinical 
evidence that WRN degradation is a biomarker of CPT 
sensitivity in breast cancer cells, where it can distinguish 
CPT- sensitive and resistant breast cancer cells. Therefore, 
WRN expression and degradation could be used to identify 
tumors which may be sensitive to CPT and its derivatives. 
However, a prospective clinical trial of Top1 inhibitor 
therapy in ER positive breast cancers would be required 
to confirm our in vitro results. Additionally we show that 
in human breast cancers, Top1 and/or WRN expression 
has prognostic and predictive significance. Top1/ WRN 
expression based stratification could be a promising 
approach to personalize Top1 inhibitor therapy in breast 
cancer patients.
MAtErIALs AND MEtHODs
cell culture
U2OS, 293T, GM637, BT-474, BT-549, MCF-
7, MDA-MB-231, T47D, ZR-75-1, HCT116, HCT116 
p53-/- and WI-38 were cultured as described [14, 21, 28]. 
For knockdown experiments, cells were infected with 
lentivirus carrying either control or WRN or RECQL4 
small hairpin RNA (shRNA) as described before [21] 
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for at least 72 hours. For overexpression, transfections 
were performed with 3 x 105 cells using 1 μg of pCMV-
tag4 plasmids with 3xFlag or 3xFlag-WRN or 3xFlag-
RECQL4, or pEGFP, pEGFP-WRN, or pcDNA3.1-HA-
ubiquitin using jetPRIME (Polyplus transfection) [21]. 
CPT (Sigma) was dissolved in DMSO, and 10 mM 
aliquots were stored at -20 0C, and cells were treated at 10 
μM unless otherwise specified. For proteasome inhibition, 
cells were treated with 10 μM MG132 (EMD Millipore) 
and for inhibiting protein synthesis, cells were pretreated 
with 10 μg/ml cycloheximide (CHX; Sigma). For 
detecting lysosomes, cells were infected with CellLight 
Lysosome-GFP baculovirus (Life technologies). For IR 
treatments, cells were grown in 6 cm plates and irradiated 
with 1 or 10 gy of 137Cs gamma rays.
Immunoblotting
Cells were lysed in either IP lysis buffer [14] or 
RIPA buffer (Thermo Scientific) and briefly sonicated. 
The Subcellular Protein Fractionation kit for Cultured 
Cells (Thermo Scientific) was used to isolate proteins from 
specific cellular compartments i.e. cytoplasm, cytoplasmic 
organelles, nuclear soluble and chromatin. Proteins were 
detected by Western blotting [14] using in house (anti-
WRN, -RECQL4, -RECQL5), Abcam (anti-CtIP, -XLF), 
Millipore (histone 3), BD Pharmingen (anti-53BP1, 
-calretuculin, -Top1) and Santa Cruz (anti-RECQL1, 
-Ku80, -actin, -tubulin) antibodies and quantitated by 
using ImageJ 1.46r software (National Institutes of Health, 
USA).
Quantitative real-time polymerase chain reaction 
(qrt-Pcr)
Total cellular RNA was isolated using RNeasy RNA 
isolation kit (Qiagen) from 500,000 cells treated with or 
without CPT. Complementary DNA (cDNA) synthesis and 
qRT-PCR were performed in a single reaction tube with 15 
ng of RNA using gene-specific primers and SuperScript 
III Platinum SYBR Green One-Step qRT-PCR kit (Life 
Technologies). Reverse transcription and qRT-PCR were 
performed according to manufacturer’s protocol in a 
7900 Fast Real-Time PCR system (Applied Biosystems). 
Hs00262956_m1 (RECQL1), Hs00172060-m1 (BLM), 
Hs01087915_m1 (WRN), Hs01548660_g1 (RECQL4), 
Hs00188633_m1 (RECQL5) and Hs02758991_g1 
(GAPDH) primer sets (Applied Biosystems) were used 
for quantitating mRNA.
Immunostaining and microscopy
Cells grown in chambered glass slides (Labtek) 
for 24 hours in the presence or absence of bacullovirus 
expressing lysosome specific GFP were treated with CPT. 
Post treatment, cells were fixed and immunostained for 
WRN and 53BP1 as described before [21] and imaged 
with a Zeiss LSM510 (40X objective) microscope and 
Volocity 3D image analysis software (Perkinelmer). 
Time-lapse microscopy was performed with U2OS cells 
stably expressing YFP-WRN using the above mentioned 
microscope settings supported with temperature and CO2-
regulated incubation chamber.
cell survival and proliferation assays
Cells (5000/well) were seeded in triplicates in a 96-
well plate and treated with CPT for 24h. Cell viability and 
proliferation were assayed according to the manufacturer’s 
protocol using WST-1 reagent (Roche). Cell viability 
was calculated from three independent experiments and 
normalized to no treatment controls.
SA-β-gal assay
Three biological repeats of SA-β-gal staining was 
performed with control, WRN and RECQL4 expressing 
cells treated with CPT for 18 hours as previously described 
[21].
WRN and Top1 mrNA expression in patient 
tumors
The METABRIC study protocol, molecular 
profiling, Tumor Marker Prognostic Studies (REMARK) 
criteria were followed [29, 42] to study WRN and Top1 
mRNA expression. Gene copy number was assayed on the 
Affymetrix SNP 6.0 platform (data available through the 
European Genotype Archive, http://www.ebi.ac.uk/ega/
page.php under accession Number: EGAS00000000082). 
The mRNA expression was analyzed as before [29, 43] by 
using WRN (ILMN_1679881) and Top1 (ILMN_2192316) 
specific probes. 
Breast cancer specific survival (BCSS) was defined 
as the number of months from diagnosis to the occurrence 
of BC related-death and the data was analyzed using SPSS 
(SPSS, version 17 Chicago, IL) as described before [43]. 
Cumulative survival probabilities were estimated using the 
Kaplan-Meier method, and differences between survival 
rates were tested for significance using the log-rank test 
and multivariate analysis for survival was performed using 
the Cox proportional hazard model as described before 
[43]. 
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